GENinCode Plc Announces Clinical Publication Highlighting CARDIO inCode-Score's Role in Predicting Heart Disease Risk

GENinCode Plc, the company specializing in polygenic risk assessment for cardiovascular diseases and ovarian cancer, recently announced a significant breakthrough with the publishing of a study in the American Journal of Preventive Cardiology. This study, involving over 63,000 participants from the Kaiser Permanente Northern California Genetic Epidemiology Resource in Adult Health and Aging (GERA) cohort, demonstrated the effectiveness of the CARDIO inCode-Score in predicting the risk of coronary heart disease (CHD) across a diverse population.

The research highlighted how the CARDIO inCode-Score can pinpoint individuals at an elevated risk of CHD, allowing for targeted lifestyle and therapeutic interventions. Notably, previous data has shown that high-risk individuals can reduce their risk of CHD by 52% through adopting a favorable lifestyle. The study advocates for integrating polygenic risk scores with traditional clinical assessments to enhance the preventive healthcare framework against CHD.

GENinCode is progressing with the commercialization of the CARDIO inCode-Score, partnering with leading healthcare institutions to refine heart attack risk estimations over an individual's lifetime. Additionally, the company has submitted its CIC-Score for FDA approval, marking a critical step in making this predictive tool accessible to healthcare providers and patients.

The company will be showcasing this innovative technology at the upcoming Annual ACC Meeting, emphasizing its commitment to advancing cardiovascular disease prevention and care.